Last reviewed · How we verify

Chlorthalidone (CTD)

VA Office of Research and Development · Phase 3 active Small molecule

Chlorthalidone is a thiazide-like diuretic that inhibits sodium and chloride reabsorption in the distal convoluted tubule of the kidney, reducing blood volume and lowering blood pressure.

Chlorthalidone is a thiazide-like diuretic that inhibits sodium and chloride reabsorption in the distal convoluted tubule of the kidney, reducing blood volume and lowering blood pressure. Used for Hypertension, Edema associated with congestive heart failure, renal disease, or hepatic cirrhosis.

At a glance

Generic nameChlorthalidone (CTD)
Also known asCTD
SponsorVA Office of Research and Development
Drug classThiazide-like diuretic
TargetSodium-chloride cotransporter (NCC)
ModalitySmall molecule
Therapeutic areaCardiovascular
PhasePhase 3

Mechanism of action

By blocking the sodium-chloride cotransporter in the kidney's distal convoluted tubule, chlorthalidone increases urinary sodium and water excretion, leading to decreased intravascular volume and reduced peripheral vascular resistance. This results in antihypertensive effects. Chlorthalidone is a long-acting thiazide-like diuretic with a longer half-life and greater potency compared to hydrochlorothiazide.

Approved indications

Common side effects

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: